Fresenius Kabi Pharmaceuticals Holding, Inc.

Fresenius Kabi Pharmaceuticals Holding, Inc. develops, manufactures, and markets injectable pharmaceutical products in North America. Its oncology products include Carboplatin for the advanced ovarian carcinoma; Doxorubicin for breast cancer; Fludarabine for B-cell chronic lymphocytic leukemia; Fluorouracil to inhibit the growth of cancer cells; Ifosfamide to treat germ cell testicular cancer; Irinotecan for cancer of the large intestine and rectum; Mesna for the side effects related to chemotherapy drugs; Paclitaxel Injection for the carcinoma of the ovary and non-small cell lung cancer; Cisplatin Injection for metastatic testicular tumors; Oxaliplatin; and Topotecan for Injection for small cell lung cancer sensitive disease. Its anti-infective products comprise Aztreonam to treat infections caused by susceptible gram-negative microorganisms; Ampicillin for the infections of the skin, central nervous system, heart, respiratory tract, sinuses, ear, and kidney; Ampicillin and Sulbactam for skin and skin structure, intra-abdominal, and gynecological infections; Azithromycin for pneumonia and pelvic inflammatory disease; Cefotetan for surgical prophylaxis; and Vancomycin for staph, strep. Its critical care products consist of Heparin for blood clotting; Oxytocin to control postpartum bleeding; Levothyroxine, a replacement therapy in hypothyroidism; Hydralazine for hypertension and congestive heart failure; Thiamine for thiamine deficiency; Chorionic for inducing ovulation and pregnancy in infertile females; Protamine for heparin overdoses; Dexamethasone; Diprivan; and Naropin for producing anesthesia for surgery. It markets its products through its sales force. The company was formerly known as APP Pharmaceuticals, Inc. and changed its name to Fresenius Kabi Pharmaceuticals Holding, Inc. in September 2008. The company was founded in 1996 and is based in Delaware. The company operates as a subsidiary of Fresenius Kabi AG.